Breaking News, Trials & Filings

PTC Therapeutics’ Gene Therapy for AADC Deficiency Approved by FDA

The gene therapy is indicated for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics Inc.’s gene therapy for the treatment of AADC deficiency, making it the first-ever gene therapy approved in the United States that is directly administered to the brain.   “PTC has once again pioneered a new approach to treating highly morbid neurologic diseases,” said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. “I am proud of our team’s unwavering commitment to achieve this...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters